FDCDDQ
APGE icon

Federation des caisses Desjardins du Quebec’s Apogee Therapeutics APGE Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10
Closed -$397 – 2891
2025
Q3 		$397 Hold
10
– – ﹤0.01% 2745
2025
Q2 		$434 Hold
10
– – ﹤0.01% 2588
2025
Q1 		$374 Hold
10
– – ﹤0.01% 2522
2024
Q4 		$453 Buy
+10
New +$510 ﹤0.01% 2398

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's APGE Position: Q4 2025 in Review

Federation des caisses Desjardins du Quebec sold out of Apogee Therapeutics (APGE) in Q4 2025, closing a stake of 10 shares — an estimated $397 sold.

Federation des caisses Desjardins du Quebec first reported a position in APGE in Q4 2024 and held it in 4 quarters. The position peaked at $453 in Q4 2024. 206 funds tracked by Wall St. Rank hold APGE as of Q4 2025.

  • Federation des caisses Desjardins du Quebec reported no remaining Apogee Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Federation des caisses Desjardins du Quebec sold 10 Apogee Therapeutics shares in Q4 2025, an estimated $397.
  • Federation des caisses Desjardins du Quebec first reported a position in Apogee Therapeutics in Q4 2024 and held it in 4 quarters.
  • Federation des caisses Desjardins du Quebec's Apogee Therapeutics position peaked at $453 in Q4 2024.
  • 206 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2025.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2025, filed 12 Feb 2026.